ArticleProbiotics and antimicrobial proteins2026
Gassericins from Lactobacillus Paragasseri K7: Preparative Isolation and Discovery of Dose-Dependent Anti-Inflammatory Effects.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Gassericins K7 are heterodimeric bacteriocins produced by Lactobacillus paragasseri K7. Their biological characterisation has been limited by challenges in obtaining these compounds in sufficient purity and quantity. In this study, we used a preparative isolation and purification workflow for gassericins K7, combining ammonium sulphate precipitation, Amberlite XAD-16 extraction, and reversed-phase chromatography. Mass spectrometry confirmed the presence of all four peptide components GasK7A α, GasK7A β, GasK7B α, and GasK7B β in the pooled preparation, including GasK7A β, identified here for the first time in natural isolates of this strain. The purified bacteriocin preparation exhibited strong antibacterial activity against indicator strain Latilactobacillus sakei NCDO 2714. Cytotoxicity testing in RAW 264.7 macrophages revealed minimal effects at concentrations up to 50 µg/ml, with only a modest reduction in cell viability observed at 100 µg/ml. Subsequent evaluation of immunomodulatory properties demonstrated a clear dose-dependent anti-inflammatory effect in LPS-stimulated macrophages. Treatment with gassericins K7 reduced nitric oxide (NO) production, downregulated inducible nitric oxide synthase (iNOS) expression, and suppressed secretion of the pro-inflammatory cytokines TNF-α and IL-6. Importantly, exposure of macrophages to gassericins alone did not elicit any inflammatory response. These findings provide the first evidence of anti-inflammatory activity of purified gassericins K7 in eukaryotic immune cells and highlight their potential as postbiotic components or biotherapeutic candidates for inflammatory disorders. The preparative method used in this study enables the production of gassericins K7 in quantities sufficient for advanced in vitro and in vivo investigations, facilitating future development of bacteriocin-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.